Sofosbuvir has ushered in a new era of hepatitis C treatment with its strong inhibition on the replication of hepatitis C virus, favorable safety profile and less interactions with other drugs. Sofosbuvir-based regimens have been included as the first-line therapies for the treatment of adults with chronic hepatitis C (CHC) in international guidelines. Available clinical trial data show that sofosbuvir with ribavirin and ledipasvir/sofosbuvir are highly efficacious and safe in CHC patients aged 3-17 years old; therefore, they can meet the unmet medical needs of adolescents and children with CHC in China. Furthermore, the pan-genotypic sofosbuvir/velpatasvir is being investigated in adolescents and children with CHC, which is expected to make the treatment in such patients more convenient upon approval.直接抗病毒药物索磷布韦抑制丙型肝炎病毒能力强、安全性良好，且与其他药物的相互作用较少，开创了丙型肝炎治疗的新时代，以索磷布韦为基础的方案已成为国际指南中治疗成人慢性丙型肝炎的推荐方案。现有临床试验数据表明，索磷布韦联合利巴韦林、来迪派韦索磷布韦在3～17岁的慢性丙型肝炎患者中疗效高、安全性好，因此将能够满足中国未成年慢性丙型肝炎患者亟待解决的医疗需求。泛基因型方案索磷布韦维帕他韦于未成年患者中正在进行临床试验，该方案一旦获批准，将为儿童及青少年患者的丙型肝炎治疗带来更多便利。.
